Introduction
Platelet inhibitors, such as aspirin and P2Y 12 inhibitors (clopidogrel, ticagrelor, and prasugrel), are widely used to prevent and treat stroke and thromboembolic diseases. 1, 2 Although platelet inhibitors are not recommended for primary stroke prevention, 3 when stroke occurs many patients are already taking these drugs for the indications of ischaemic heart disease and other non-stroke conditions.
Pre-admission use of oral anticoagulants is known to worsen the prognosis of haemorrhagic stroke, 4 but the impact of pre-admission antiplatelet drug use on the prognosis of haemorrhagic and ischaemic stroke is poorly understood. As bleeding is a frequent complication of treatment with aspirin and P2Y 12 inhibitors, 5, 6 especially when combined, these drugs may worsen stroke prognosis. [7] [8] [9] [10] [11] [12] [13] However, current evidence is conflicting and limited to small studies of mixed anticoagulant and platelet inhibitor treatment. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Because of the reimbursement scheme, the proportion of low-dose aspirin sales dispensed by prescription is high, reaching 92% in 2012. 20 This makes use of filled prescriptions for low-dose aspirin a valid proxy for actual use. 20 The Danish Civil Registration System 18 assigns a permanent, unique identification number to every Danish inhabitant at birth and to residents upon immigration. 18 This identifier allows unambiguous, individual-level linkage between Danish national registries. In the current study, we used the personal identifiers to link the Danish National Patient Registry (DNPR) and the National Health Service Prescription Database (NHSPD). 19, 21 The NHSPD achieved full national coverage on 1 January
2004. The study period began 6 months after this date to ensure at least 6 months of complete pre-admission prescription history for study patients.
The study was approved by the Danish Data Protection Agency (record number 2011-41-5755). As this study did not involve contact with patients or any intervention, according to Danish law, it was not necessary to obtain permission from a Danish Scientific Ethical Committee.
Stroke
We used the DNPR 21 to identify all patients with a first-time hospitaliza- 21 The discharging physician assigns an ICD code corresponding to the primary diagnosis made during a hospitalization or outpatient clinic visit, as well as ICD codes for an optional number of secondary diagnoses. The index date was defined as the date of hospital admission for stroke. We identified primary and secondary inpatient discharge diagnoses of ischaemic stroke, intracerebral haemorrhage (ICH), and subarachnoid haemorrhage (SAH) using the DNPR (ICD-10 codes provided in Supplementary material online, Table S1 ). Patients were included in the study if they died in the ambulance on the way to the hospital or during their hospital admission, but not if they died at home. Unspecified strokes (ICD-10 code I64) were not included in the primary analyses, because this diagnosis may cover either an ischaemic or a haemorrhagic stroke. However, they were included in a sensitivity analysis, as described below. Transient cerebral ischaemia was not included, because the positive predictive value of this diagnosis is lower than for stroke. 22 The DNPR provided information on diagnostic imaging procedures used to verify stroke diagnoses [computed tomography (CT) and magnetic resonance imaging (MRI)]. Among all stroke patients, 86% had a CT performed upon admission and 12% had an MRI performed ( Table 1) . Among patients with ischaemic stroke, 3049 (6.6%) received thrombolytic therapy within two weeks around the date of stroke diagnosis. Among patients with SAH, 1667 (39%) received neurosurgical treatment within 2 weeks around the date of stroke diagnosis. Among patients with ischaemic stroke treated with aspirin and clopidogrel, 37.5% underwent percutaneous coronary intervention within the previous 12 months prior to stroke diagnosis, indicating that percutaneous coronary intervention was a frequent indication for dual antiplatelet therapy. Among patients with ischaemic stroke treated with aspirin alone, a total of 9.4% had previously undergone percutaneous coronary intervention at any time before stroke, and 0.8% had undergone percutaneous coronary intervention within the previous 12 months.
Platelet inhibitor use
We used the NHSPD 19 to identify all prescriptions for aspirin, clopidogrel, ticagrelor, and prasugrel redeemed by study patients before their stroke admission date. In the NHSPD, each drug is classified according to the international Anatomical Therapeutical Chemical (ATC) system, and each prescription record contains information on drug dosage, date of dispensing, number of packets or units, and number of tablets per package. All data are recorded at the level of the individual patient, and the completeness of the database is high. 19 We identified prescriptions for platelet inhibitors according to the ATC codes listed in Supplementary material online, Table S1 . Because the numbers of ticagrelor and prasugrel users were too small to permit further statistical inference, we excluded patients taking these drugs from mortality analyses. In Denmark, secondary cardiovascular prevention with aspirin and clopidogrel is typically recommended in the following doses: aspirin 75-150 mg daily and clopidogrel 75 mg daily. In Denmark, prescriptions for aspirin and clopidogrel are typically dispensed for 100 days. As previously described, 23 we calculated exposure time assuming that patients take one tablet per day, i.e. the number of tablets in the package from the last redeemed prescription plus 7 days (to account for overlapping periods) equalled exposure time at risk. High-dose aspirin (500 mg) was excluded from the primary analyses, but included in a sensitivity analysis, as described below. We defined current users of a platelet inhibitor as patients whose index date was in the interval between the date of drug dispensing and the date of drug dispensing plus the number of days supplied plus seven days. 23 Because inclusion of long-term current users may result in underascertainment of adverse drug effects arising shortly after treatment initiation, we performed a sensitivity analysis categorizing current users into new users and long-term users. We defined new users as current users with only one redeemed prescription and long-term users as current users with more than one redeemed prescription. 24 We defined former users as those whose admission date fell after the most recent redemption date plus the number of days of exposure (i.e. pills dispensed). We defined non-users (reference group) as patients who did not redeem a prescription within 180 days before their index date.
Mortality
We obtained data on all-cause 30-day mortality from the Danish Civil Registration System. 18 This registry contains data on vital status and migration, updated daily, for the entire Danish population since 1968. 18 
Comorbidity
We ascertained comorbidity from inpatient and outpatient hospital diagnoses recorded in the DNPR prior to the index date. We did not include emergency room visits, because the positive predictive value for emergency room diagnoses is rather low. We included information on risk factors for stroke (myocardial infarction, atrial fibrillation or flutter, and intermittent arterial claudication). 25 We calculated any additional comorbidity burden using the Charlson Comorbidity Index (CCI), which we modified by excluding hemiplegia, cerebrovascular diseases, myocardial infarction, congestive heart failure, chronic obstructive pulmonary disease, and diabetes. 26 
Comedications
Since several drugs other than aspirin and P2Y 12 inhibitors may influence stroke prognosis, we used the NHSPD to obtain prescription information for the following medications: angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonists, beta-blockers, calcium antagonists, statins, non-aspirin non-steroidal anti-inflammatory drugs, dipyridamole, vitamin K antagonists, non-vitamin K antagonist oral anticoagulants (dabigatranetexilat, apixaban, and rivaroxaban), and systemic glucocorticoids. As dipyridamole is used almost exclusively for secondary stroke prevention, patients with one or more prescriptions for dipyridamole filled at any time were excluded (n = 2143) from the study. To focus on platelet inhibitors only, patients with one or more filled prescriptions for oral anticoagulants within at least 6 months of stroke diagnosis were also excluded (n = 5237). 
Statistical analysis
We characterized the cohorts according to gender, age, comorbidity, comedication use, and performance of CT or MRI of the brain (yes/no) during hospital admission for stroke, presumed to represent CT or MRI of the brain. We followed all patients from date of admission until death, emigration, 31 December 2012, or for 30 days, whichever came first. We computed and plotted the 30-day mortality function as one minus the Kaplan-Meier estimate. We used a Cox proportional-hazards regression analysis to compute hazard ratios as measures of mortality rate ratios (MRRs) and 95% confidence intervals (CIs) within 30 days for current platelet inhibitor use compared with non-use. In the primary analysis, we used a multivariable model adjusting for age categories, sex, previous myocardial infarction, individual comedications, CCI score level (grouped in 0, 1-2, >2), and the following individual comorbidities: atrial fibrillation or flutter, heart valve disease, intermittent arterial claudication, venous thromboembolism, congestive heart failure, diabetes, angina pectoris, hypertension, obesity, alcoholism, chronic obstructive pulmonary disease, and kidney disease, as presented above. We performed five sensitivity analyses. Among all cerebrovascular events, a total of 32% were classified as unspecified strokes in the study period. 27 Since two-thirds of unspecified strokes in the DNPR are known to be ischaemic strokes, 22 we included both diagnoses (ICD-10 codes I63
and I64) to increase precision. Second, to increase the positive predictive value of registry-based stroke diagnoses, we restricted to patients who had a CT or MRI scan performed during their hospital admission. Third, to examine the sensitivity of estimates to time since treatment initiation, we looked at new users and long-term users separately, as defined above. Fourth, we examined current aspirin use according to daily dose, i.e. lowdose (75-150 mg) or high-dose (500 mg), compared with non-use. Finally, as the proportion of low-dose aspirin sales associated with prescriptions has been increasing, we added a sensitivity analysis stratifying stroke mortality by calendar period (2004-2006, 2007-2009, and 2010-2012) . We stratified analyses by sex, age group, and presence/absence of previous myocardial infarction, atrial fibrillation or flutter, diabetes, chronic obstructive pulmonary disease, hypertension, and venous thromboembolism. The proportional hazard assumption was visually assessed by log-log plots and found to be valid. Analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
The selection of the final study population is shown in the flow diagram (Supplementary material online, Figure S1 ). Patient characteristics are presented in Table 1 . We identified a total of 87 645 patients with a first-time hospitalization for specified stroke, among which 73 477 (84%) patients had ischaemic strokes, 9930 (11%) had ICH, and 4238 (5%) had SAH. A total of 19 226 (22%) stroke patients were current platelet inhibitor users, 2827 (3%) were former users, and 65 592 (75%) were non-users.
The most notable differences in patient characteristics were the greater likelihood of current platelet inhibitor users to be older, to take comedications, to have heart disease (particularly hypertension and previous myocardial infarction), and to have a higher level of comorbidity compared with non-users ( Table 1) .
Mortality
Absolute 30-day mortality rates, as well as crude and adjusted 30-day mortality rate ratio estimates, are presented in platelet inhibitor non-users, overall 30-day stroke mortality was 12.0% (6.9% mortality from ischaemic stroke, 30% mortality from ICH, and 21% mortality from SAH). Compared with non-use, current use of aspirin was associated with increased mortality among patients with ICH [adjusted MRR (aMRR) = 1.19, 95% CI 1.09-1.31]. Although CIs were wider, we saw similarly increased point estimates for patients with SAH (aMRR = 1.21, 95% CI 0.97-1.51), whereas mortality from ischaemic stroke was not increased (aMRR = 1.02, 95% CI 0.94-1.11) ( Table 2) .
Compared with non-users, current users of both aspirin and clopidogrel had reduced 30-day mortality from ischaemic stroke (aMRR = 0.67, 95% CI 0.48-0.94). Among patients with intracranial bleeds, mortality from ICH and SAH was increased in both exposure groups, although CIs were wide for users of aspirin and clopidogrel ( Table 2 ). According to the point estimates, stroke mortality was increased by approximately 20-25% for ICH (aspirin only: aMRR = 1.19, 95% CI 1.09-1.31; aspirin þ clopidogrel: aMRR = 1.26, 95% CI 0.84-1.91) and SAH (aspirin only: aMRR = 1.21, 95% CI 0.97-1.51; aspirin þ clopidogrel: aMRR = 1.19, 95% CI 0.51-2.78), but CIs were relatively wide. We found no substantial differences when comparing mortality risk among users of low-dose and high-dose aspirin with that among non-users ( Table 3) .
The 30-day bleeding risk was substantially increased after ICH and SAH, but no excess risk was seen among platelet inhibitor users compared with non-users (aspirin only: adjusted rate ratio = 1.03, 95% CI 0.83-1.28; aspirin þ clopidogrel: adjusted rate ratio = 0.31, 95% CI 0.08-1.29). Bleeding risk was lower among non-users and aspirin only users, while it was unaffected among users of aspirin and clopidogrel (Supplementary material online, Table S2 ).
In the sensitivity analyses, results were robust when unspecified strokes were included as ischaemic strokes (Supplementary material online, Table S3 ). When current users were categorized into new users and long-term users, point estimates were higher for ischaemic stroke and ICH among long-term users than among new users, compared with non-users, but CIs were overlapping (Supplementary material online, Table S4 ). Mortality risk estimates remained robust when analyses were restricted to stroke diagnoses confirmed by CT or MRI (Supplementary material online, Table S5 ) and when stratified by calendar period (Supplementary material online, Table S6 ). Although statistically significant interactions were seen for some variables, especially age and previous myocardial infarction and venous thromboembolism, we found no substantial effect modification of the risk estimates in the stratified analyses when looking at the point estimates ( Table 4) .
Discussion
Platelet inhibitor users hospitalized for first-time ICH had 20-25% increased 30-day stroke mortality compared with non-users. In contrast, mortality was reduced by approximately 35% in users of both aspirin and clopidogrel who were hospitalized for first-time ischaemic stroke. Use of aspirin alone was not associated with ischaemic stroke mortality.
Our study of a large stroke cohort extends previous research by examining stroke mortality in the current era of platelet inhibition, which often includes both aspirin and a P2Y 12 inhibitor. 28 According to most previous studies, platelet inhibitors worsen stroke prognosis, especially for haemorrhagic strokes. [7] [8] [9] [10] [11] [12] [13] Still, evidence is conflicting, with some studies suggesting no association. 14-16 Kwok et al.
11
showed in their single-hospital study that prior aspirin use was associated with increased 30-day mortality (adjusted odds ratio = 2.36, 95% CI 1.18-4.71) following ICH, but not following ischaemic stroke. In contrast, Myint et al. 17 showed in a much larger study that previous antithrombotic treatment (platelet inhibitors and/or anticoagulants) was associated with significantly reduced in-hospital mortality (adjusted odds ratio = 0.82, 95% CI 0.80-0.84) after ischaemic stroke. Khan et al. 13 found that previous treatment with two antiplatelet drugs (mainly aspirin and clopidogrel) (adjusted odds ratio = 1.50, 95% CI 1.39-1.63), but not with one antiplatelet drug, was associated with higher in-hospital mortality in patients with ICH. Our study, which included a large number of patients treated with clopidogrel and no patients on anticoagulant treatment, seems to confirm these results, but indicates smaller relative mortality risks. The exact mechanisms underlying our findings are not clear, but large haematoma volume predicts poor ICH prognosis 29 and increased ICH mortality in users of platelet inhibitors is thought to result from enlarged haematomas caused by blunted platelet function. 30 In relatively small cohorts of less than 300 ICH patients, preadmission platelet inhibitor use has been associated with increased haemorrhage volume, 15, 16, 31 haemorrhage expansion, 15 or shortterm adverse clinical outcome. 15, 16 Importantly, reported use of platelet inhibitors may not correspond to actual platelet inhibition at time of stroke. 32 Early platelet transfusion seems to improve platelet activity after ICH among users of platelet inhibitors, 33 however, reversing platelet inhibition by platelet transfusion was inferior to standard care in a randomized trial including 190 patients with acute ICH, 34 and current guidelines discourage this strategy. 35 A systematic review concluded that mortality is significantly increased in platelet inhibitor users who suffer ICH (multivariable-adjusted odds 7 yet the association was considered modes. 7 An important issue is that many patients prescribed platelet inhibitors likely discontinue them after their ICH and perhaps do not restart them, although in some cases platelet inhibitor treatment may still be indicated. Although SAH accounts for only 5% of all strokes, 36 SAH patients tend to be younger than other stroke patients and the short-term case fatality rate is as high as 50%, 36 making the loss of productive lifeyears at the population level comparable with that from ischaemic stroke. 37 We found that aspirin use with or without clopidogrel seemed to increase SAH mortality, but due to the relatively smaller number of patients with SAH, CIs were less precise and did not allow firm conclusions. Consistently, we have also previously shown that aspirin use increases incident SAH risk. 23 Theoretically, platelet inhibitor use may cause more severe SAHs, increasing risk of immediate death. If so, these patients' likelihood of being hospitalized would be low. As our study included only inpatient stroke diagnoses, it is thus possible that it underestimates the association between platelet inhibitor use and SAH-related mortality.
A key finding of our study is that aspirin alone was not associated with improved outcome after ischaemic stroke. Although aspirin reduces the incidence of ischaemic stroke in primary and secondary prevention trials, 38 its role in improving stroke prognosis and reducing mortality has been disputed. 38 In contrast to our results, some previous studies showed milder clinical deficits and reduced mortality in aspirin users suffering a first-time or recurrent ischaemic stroke, compared with non-users. [39] [40] [41] [42] However, in agreement with our findings, other studies found no beneficial effect of pre-stroke aspirin use. [43] [44] [45] [46] Altogether, the evidence remains unclear.
A large proportion (37.5%) of patients treated with aspirin and clopidogrel who benefited from reduced 30-day mortality following hospitalization for ischaemic stroke in this study had recently undergone percutaneous coronary intervention. According to current practice, these patients are usually prescribed dual antiplatelet therapy (aspirin plus a P2Y 12 inhibitor) for 6-12 months depending on stent type and comorbidity.
2 While aspirin and clopidogrel provide more efficient platelet inhibition and prevention of arterial thrombus formation than aspirin alone, 2 the combined treatment increases bleeding risk and thus is not recommended for stroke prevention 1, 3 or long-term prevention of ischaemic heart disease. The influence of platelet inhibitors on ischaemic stroke outcome reflects complex mechanisms. First, platelet-dependent thrombus formation involves not only aggregation, as platelets contribute to processes beyond haemostasis and thrombosis. These processes include inflammation, innate immunity, wound healing, and maintenance of vascular integrity. 47 Second, platelet inhibitors possess functions other than inhibition of platelet aggregation. These functions, encompassing plaque stabilization, compensatory vasodilatation, and reduction of free radical-induced injury and thrombus extension, 41 may mitigate damage during a stroke. As expected, 30-day bleeding risk varied substantially according to stroke subtype, with very high risk estimates seen for ICH and SAH. Interestingly, pre-admission platelet inhibitor use did not seem to affect bleeding risk. This suggests that the excess 30-day ICH mortality risk seen among platelet inhibitor users was not driven by bleeding events.
Given the observational design of our study, caution should be given concerning the impact of our results on the clinical management of stroke patients. Nonetheless, our study highlights for clinicians that use of platelet inhibitors when stroke occurs carries important prognostic implications during the first month.
Study strengths and limitations
We used nationwide population-based registries with complete follow-up for death, thereby largely eliminating selection bias. As the DNPR covers all hospital admissions in Denmark, our results are not skewed by selective inclusion of specific hospitals, health insurance systems, or age groups. Correlation between drug dispensing and drug use is likely to be high, 19 since only partial reimbursement of drug expenses is provided, and all examined drugs, except aspirin, were unavailable over-the-counter in Denmark during the study period. Unreported use of aspirin cannot explain our results, as it would tend to reduce the magnitude of the true association. 20 The study is strengthened by our use of a 17-year minimum washout period (1977 to at least 1993) to increase the likelihood of distinguishing first-time from recurrent strokes. An important limitation is our lack of data on stroke severity, functional outcome, and lifestyle factors that might be associated with stroke risk. However, we indirectly adjusted for at least some lifestyle factors by including coronary artery disease, pulmonary disease (through CCI scores), and cancer in our regression model. We were also unable to examine the association between pre-admission use of ticagrelor/prasugrel and stroke mortality, because the patient numbers were low and yielded imprecise estimates. The number of unspecified strokes implied a relatively high degree of unspecified coding (rather than lack of specific diagnosis). The main analysis was, however, based only on specified strokes. We did not have data on causes of death. We therefore restricted the outcome to short-time mortality to have the outcome most likely related to the index event of stroke (although other causes of death such as myocardial infarction may also play a role). Finally, ischaemic heart disease, the primary indication for platelet inhibitor use, substantially increases morbidity and mortality. 48 We therefore cannot rule out that our results might be explained in part by confounding from the underlying condition for which platelet inhibitors were prescribed.
Conclusion
We conclude that among patients hospitalized for first-time ICH, pre-admission use of aspirin with or without clopidogrel was associated with increased 30-day stroke mortality compared with non-use. Mortality seemed equally high among patients hospitalized for firsttime SAH. In patients hospitalized for first-time ischaemic stroke, 30-day mortality was reduced in users of both aspirin and clopidogrel, while it was unaffected in users of aspirin alone.
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